Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
- Update frequency
- every day
- Average duration
- 26 minutes
- Episodes
- 1069
- Years Active
- 2020 - 2025
S2 E10 — Before NASH-TAG, Conversations With Co-Directors
NASH-TAG Co-directors Vlad Ratziu and Michael Charlton talk with Roger Green about the upcoming conference, after which Roger discusses the SurfingNASH coverage plan for NASH-TAG.
If you…
S2-E9.2—Drug-Free Treatment of Early Fatty Liver Disease: Issues for Public Health
Donna Cryer joins the Surfers to consider some of the public health issues and implications surrounding treatment of Early Fatty Liver disease and related metabolic diseases. EXTRA: Lo…
S2-E9.3 — Introducing LIVErHEALTHY: a program for patients with Early Fatty Liver disease
Executives from Echosens, Chronwell and ModifyHealth join to introduce LIVErHEALTHY, their integrated program for early Fatty Liver disease that integrates non-invasive monitoring, tech…
S2-E9.1—Drug-Free Treatment of Early Fatty Liver Disease: Identity matters
Donna Cryer and Roger Green lead a conversation of why identity matters for patients trying to resolve fatty liver disease without medication, while Stephen Harrison and Louise Campbell…
S2-E9 - Novel Approaches to Drug-Free Treatment of Early Fatty Liver Disease
Donna Cryer joins the Surfers to discuss the importance of identity in lifestyle modification, after which our sponsors from Echosens present LIVErHEALTHY, a program that combines non-i…
S2-E8.3 - Previewing NASH-TAG 2021: Two intriguing side conversations
This conversation integrates two significant side conversations during the review of the NASH-TAG 2021 agenda, one about creativity and intellectual ferment and the other about what we …
S2-E8.2 - Previewing NASH-TAG 2021: Day Two
Stephen Harrison previews Day Two of NASH-TAG while Ian Rowe, Louise Campbell, and Roger Green the issues that each of them anticipates most eagerly.
Stephen Harrison previews the secon…
S2-E8.1 - Previewing NASH-TAG 2021: Day One
Stephen Harrison discusses the history of NASH-TAG and what makes it special while previewing Day One of the 2021 meeting.
In this conversation, Stephen Harrison and Roger Green share t…
S2-E8 - Previewing NASH-TAG 2021
Stephen Harrison previews NASH-TAG 2021, the pre-eminent NASH drug development meeting, which will take place from March 10-12.
This year marks the 5th annual NASH-TAG, a meeting focuse…
S2-E7.3 - The newer diabetes drugs and NASH: Educating and Motivating Stakeholders
The panelists consider the barriers to bringing NASH into central consciousness in diabetes therapy and some keys to success.
Louise Campbell and Roger Green discuss issues and challenge…
S2-E7.2 - The Newer Diabetes Drugs and NASH: How T2D Patients are likely to respond
Wayne Eskridge describes some of the opportunities and concerns that affect diabetic patients might experience as they learn about NASH and the liver issues related to diabetes.
Patient,…
S2-E7.1 - The Newer Diabetes Drugs and NASH: Modes of Action
Jörn Schattenberg reviews modes of action for GLP-1 agonists and SGLT-2 inhibitors and discusses the data that exist in NAFLD and NASH.
The group considers scientific issues surrounding…
S2-E7 - The Newer Diabetes Drugs and Patients with NASH
Jörn Schattenberg and Fatty Liver Foundation President Wayne Eskridge join Louise and Roger to consider the current and future roles that GLP-1 receptor agonists like semaglutide and SG…
S2 E6.3 - #RealTalk: Trial Recruiting Challenges: Traps to Avoid in designing patient protocols for NASH Trials
Three experience NASH trial site execs identify at least 11 specific things to consider when designing your trial protocols.
Stephen Harrison challenges colleagues Naim Alkhouri and Rash…
S2 E6.2 - #RealTalk: Trial Recruiting Challenges: Educating Physician during the pandemic
The panel explores three less obvious ways that the COVID-19 pandemic has affected the ability to recruit the right patients into clinical trials.
This week, SurfingNASH discusses why re…
S2 E6.1 - #RealTalk: Trial Recruiting Challenges: Daunting Numbers and Challenging Protocols
Naim Alkhouri and Dr. Rashmee Patil of the South Texas Research Institute join the Surfers to discuss misconceptions about the ease of recruiting and qualifying patients for NASH clinic…
S2 E6 - #RealTalk on Clinical Trial Design and Execution
Naim Alkhouri and Dr. Rashmee Patil of the South Texas Research Institute join the Surfers to discuss practical challenges and issues in conducting on-time, on-target NASH clinical tria…
S2 E5.5 - Bonus Interview with Suneil Hosmane: What FDA webcast means for "Wet" Diagnostics
NEW CONTENT: Suneil Hosmane joins Roger Green to discuss why he found the FDA Webcast so encouraging for liquid biomarkers.
BONUS INTERVIEW: GenFit Global Head of Diagnostics Suneil Hosm…
S2 E5.4 - Bonus Interview with Prof. Dr. Jörn M. Schattenberg: What FDA webcast means for researchers and trial sites outside the US
NEW CONTENT: Prof. Dr. Jörn M. Schattenberg joins Roger Green to discuss his highly optimistic reaction to the FDA Webcast.
BONUS INTERVIEW: Prof. Dr. Jörn M. Schattenberg and Roger Gre…
S2 E5.3 — After the FDA Webcast: Discussing Drug Development and Clinical Trial Strategies
The Surfers and guests Manal Abdelmalek, Naim Alkhouri, and Akero Therapeutics Chief Development Officer Kitty Yale discuss sections of the FDA Webcast that centered on drug development…